semaglutide bmi 26 🚨 @TheLancet RCT: Weekly #semaglutide cut heavy drinking (–41% vs –26% placebo) in alcohol use disorder + obesity. Promising for #AddictionMedicine—more research needed. 🔗 https://t.co/20nNz8iohn @NIH @NIAAAnews @WHO @NovoNordisk #GLP1 @EASLnews Semaglutide as a GLP-1 Agonist:

Whether you're in Idaho or elsewhere, the choice often comes down to personal preference regarding the convenience of daily pills versus the simplicity of weekly injections

Ethics declarations Conflict of Interest Ryo Suzuki: received lecture fees from Astellas Pharma Inc., Eli Lilly Japan K.K., Kowa Company Ltd., Mitsubishi Tanabe Pharma Corporation, MSD K.K., Novo Nordisk Pharma Ltd., Sanofi K.K., Sumitomo Pharma Co., Ltd., Teijin Healthcare Ltd

The attorneys at Bursor & Fisher, P.A

Rare (may affect up to 1 in 1,000 people) serious allergic reactions (anaphylactic reactions)

Average weight loss: 14.9% of body weight with semaglutide versus 2.4% with placebo

Severe hypoglycemia can lead to confusion, irritability, anxiety, and other mood disturbances